Ah, a good old promise of biotech riches — I haven’t dug into one of these in ages, nothing beats the wild biotech stocks that can see their share price climb 200% (or fall 90%) on a single bit of news. This tease is from Marc Lichtenfeld, whose biotech stuff we’ve looked at several times […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I have never had First Access, but have been stung by Marc Lichtenfeld when he wrote about Accuray (ARAY) for Xcelerated...